CenExel highlights industry-leading capabilities amid growing FDA momentum advancing psychedelic clinical research

Draper Archived • May 27, 2026 • 24 views

DRAPER, Utah, May 27, 2026 /PRNewswire/ -- The FDA recently announced it is shifting regulatory attention and investment for emerging psychedelic-based therapeutics treating mental health conditions. CenExel Clinical Research is answering this push with expansion to support psychedelic clinical trials…

Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original

FB X ✉️

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!